Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation



Downloads per month over past year

Yadav, Monika and Guzmán Aránguez, Ana Isabel and Pérez de Lara, María Jesús and Singh, Mandeep and Singh, Joga and Kaur, Indu Pal (2019) Bimatoprost loaded nanovesicular long-acting sub-conjunctival in-situ gelling implant: In vitro and in vivo evaluation. Materials Science and Engineering C (103). ISSN 0928-4931

[thumbnail of Postprint]
PDF (Postprint)
Creative Commons Attribution Non-commercial No Derivatives.


Official URL:


Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular pressure (IOP) lowering eye drops. Present study tends to develop and assess a novel sustained release bimatoprost loaded nanovesicular (BMT-NV) - thermosensitive in-situ gelling implant (BMT-NV- GEL-IM), for subconjunctival delivery. BMT-NVs developed using novel composition and method of preparation, (IPA/700/DEL/2014) and industrially viable methodology were characterized and evaluated comprehensively for ocular suitability. Their incorporation into an in-situ gelling formula was safe (in vitro and in vivo) and stable upon sterilization. Autoclavability was an important consideration, as a preservative-free, single-use BMT-NV- GEL-IM will avoid side- effects associated with repetitive application of drops containing preservatives like benzalkonium chloride (BAK). An extended in vitro release of BMT (80.23%) was observed for 10 days while the IOP lowering effect extended over 2 months with single subconjunctival injection of BMT-NV-GEL-IM in rats. No clinical signs of irritation, inflammation, or infection were observed in any injected eye, throughout the study, as also confirmed by histology. Furthermore, single administration of BMT-NV-GEL as topical drop lowered the IOP over 5 days. Presence of significant diffuse fluorescence in confocal microscopy of internal eye tissues post-in vivo application, as subconjunctival implant, even after 2 month and eye drops upto1 week provide direct evidence of successful sustained delivery. We thus provide an improved modality for antiglaucoma medication in patients who are challenged to adhere to a regimen of daily eye drops.

Item Type:Article
Additional Information:

Received 24 October 2018; Received in revised form 7 May 2019; Accepted 7 May 2019; Available online 10 May 2019

Uncontrolled Keywords:Glaucoma; Nanomedicine; Sustained delivery; Fluorescence; Cytotoxicity; Ocular
Subjects:Medical sciences > Medicine > Ophtalmology
Medical sciences > Optics > Eyes anatomy
Medical sciences > Pharmacy > Biochemistry
ID Code:55831
Deposited On:24 Jun 2019 07:41
Last Modified:07 May 2020 23:01

Origin of downloads

Repository Staff Only: item control page